Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wong

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Nature Communications|October 6, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerMing Lei, Michael J Overman, Jin Yao, et al.
Neuro-Oncology Practice|October 13, 2025
Clinical outcomes and management of <i>CDKN2A/B</i> homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care surveyAlexander Yuile, Laveniya Satgunaseelan, Kimberley L Alexander, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Plos One|December 31, 2025
How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemicIan C Murphy, Kelly Bryan, Muriel Burk, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2016
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte BindingPenka S Petrova, Natasja Nielsen Viller, Mark Wong, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
Ecological Applications : a Publication of the Ecological Society of America|April 17, 2024
Effectiveness of population-based recovery actions for threatened southern mountain caribouClayton T Lamb, Sara Williams, Stan Boutin, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Nature Communications|October 6, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerMing Lei, Michael J Overman, Jin Yao, et al.
Neuro-Oncology Practice|October 13, 2025
Clinical outcomes and management of <i>CDKN2A/B</i> homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care surveyAlexander Yuile, Laveniya Satgunaseelan, Kimberley L Alexander, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Plos One|December 31, 2025
How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemicIan C Murphy, Kelly Bryan, Muriel Burk, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2016
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte BindingPenka S Petrova, Natasja Nielsen Viller, Mark Wong, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
Ecological Applications : a Publication of the Ecological Society of America|April 17, 2024
Effectiveness of population-based recovery actions for threatened southern mountain caribouClayton T Lamb, Sara Williams, Stan Boutin, et al.
Pageof 10